Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice

Hepatology

Volumn 45, Issue 1, 2007, Pages 72-79

  Lebrecht, Dirk ^a   Vargas Infante, Yetlanezi A ^a   Setzer, Bernhard ^a   Kirschner, Janbernd ^a   Walker, Ulrich A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COX 4 ENZYME; CYCLOOXYGENASE 1; CYTOCHROME C OXIDASE; MALONALDEHYDE; MITOCHONDRIAL DNA; MITOCNOL; OXYGENASE; PLANT EXTRACT; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE; SUPEROXIDE; UNCLASSIFIED DRUG; URIDINE; ZALCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ORGANELLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; FATTY LIVER; IN VIVO STUDY; LIPID LIVER LEVEL; LIVER CELL; LIVER HISTOLOGY; LIVER TOXICITY; LOW DRUG DOSE; MICROVESICULAR STEATOHEPATITIS; MITOCHONDRIAL TOXICITY; MITOCHONDRION; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY CHAIN;

ANIMALS; DIETARY SUPPLEMENTS; DNA REPLICATION; DNA, MITOCHONDRIAL; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATITIS, TOXIC; LIPID METABOLISM; LIPID PEROXIDATION; MICE; MICE, INBRED BALB C; MITOCHONDRIA, LIVER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE INHIBITORS; SUCCINATE DEHYDROGENASE; URIDINE; ZALCITABINE;

EID: 33846451377     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21490     Document Type: Article

References (43)

1. Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI). Ann Intern Med 1991;115:283-284.
2. Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 2000;31:1234-1239.
3. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995;90:1433-1436.
4. Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, et al. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med 1990;322:1333-1340.
5. Morris AA, Taanman JW, Blake J, Cooper JM, Lake BD, Malone M, et al. Liver failure associated with mitochondrial DNA depletion. J Hepatol 1998;28:556-563.
6. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999;30:156-160.
7. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000;22:685-708.
8. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002;16:2165-2173.
9. Gaou I, Malliti M, Guimont MC, Letteron P, Demeilliers C, Peytavin I, et al. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J Pharmacol Exp Ther 2001;297:516-523.
10. Walker UA, Bäuerle J, Laguno M, Murillas J, Mauss S, Schmutz G, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. HEPATOLOGY 2004;39:311-317.
11. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-1105.
12. Horn DM, Neeb LA, Colacino JM, Richardson FC. Fialuridine is phosphorylated and inhibits DNA synthesis in isolated rat hepatic mitochondria. Antiviral Res 1997;34:71-74.
13. Walker UA, Venhoff N, Koch E, Olschweski M, Schneider J, Setzer B. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003;8:463-470.
14. Walker UA, Venhoff N. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther 2005;10:M117-M123.
15. Gattermann N, Dadak M, Hofhaus G, Wulfert M, Berneburg M, Loeffler ML, et al. Severe impairment of nucleotide synthesis through inhibition of mitochondrial respiration. Nucleosides Nucleotides Nucleic Acids 2004;23:1275-1279.
16. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998;53(Suppl):20-26.
17. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999;274:36031-36034.
18. Venhoff N, Zilly M, Lebrecht D, Schirmer D, Klinker H, Thoden J, et al. Uridine pharmacokinetics of Mitocnol, a sugar cane extract. AIDS 2005;19:739-740.
19. Note R, Maisonneuve C, Letteron P, Peytavin G, Djouadi F, Igoudjil A, et al. Mitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments. Antimicrob Agents Chemother 2003;47:3384-3392.
20. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005;41:1313-1321.
21. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
22. Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 2003;108:2423-2429.
23. Frings CS, Fendley TW, Dunn RT, Queen CA. improved determination of total serum lipids by the sulfo-phospho-vanillin reaction. Clin Chem 1972;18:673-674.
24. Walker UA, Auclair M, Lebrecht D, Kornprobst M, Capeau J, Caron M. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006;11:25-34.
25. Tuzgen S, Kaynar MY, Guner A, Gumustas K, Belce A, Etus V, et al. The effect of epidural cooling on lipid peroxidation after experimental spinal cord injury. Spinal Cord 1998;36:654-657.
26. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity - a challenge for the hepatologist? J Hepatol 2002;36:283-294.
27. Bodnar AG, Cooper JM, Leonard JV, Schapira AH. Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication. Biochem J 1995;305:817-822.
28. Attardi G, Yoneda M, Chomyn A. Complementation and segregation behavior of disease-causing mitochondrial DNA mutations in cellular model systems. Biochim Biophys Acta 1995;1271:241-248.
29. Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 2001;29:337-341.
30. Mandel H, Hartman C, Berkowitz D, Elpeleg ON, Manov I, Iancu TC. The hepatic mitochondrial DNA depletion syndrome: ultrastructural changes in liver biopsies. HEPATOLOGY 2001;34:776-784.
31. Vu TH, Tanji K, Holve SA, Bonilla E, Sokol RJ, Snyder RD, et al. Navajo neurohepatopathy: a mitochondrial DNA depletion syndrome? HEPATOLOGY 2001;34:116-120.
32. Pessayre D, Fromenty B, Mansouri A. Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol 2004;16:1095-1105.
33. Goormaghtigh E, Huart P, Praet M, Brasseur R, Ruysschaert JM. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys Chem 1990;35:247-257.
34. Graziewicz MA, Day BJ, Copeland WC. The mitochondrial DNA polymerase as a target of oxidative damage. Nucleic Acids Res 2002;30:2817-2824.
35. Girot R, Hamet M, Perignon JL, Guesnu M, Fox RM, Cartier P, et al. Cellular immune deficiency in two siblings with hereditary orotic aciduria. N Engl J Med 1983;308:700-704.
36. Sommadossi JP, Carlisle R, Schinazi RF, Zhou Z. Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother 1988;32:997-1001.
37. Koch EC, Schneider J, Weiss R, Penning B, Walker UA. Uridine excess does not interfere with the antiretroviral efficacy of nucleoside analogue reverse transcriptase inhibitors. Antivir Ther 2003;8:485-487.
38. McComsey GA, Setzer B, O'Riordan M, Lebrecht D, Walker UA. NucleomaxX improves clinical lipoatrophy without any change in fat mitochondrial DNA levels. 10th European AIDS Conference; November 17-20, 2005; Dublin, Ireland 2005 [Abstract].
39. Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 2005;28:53-66.
40. Bauerle J, Laguno M, Mauss S, Mallolas J, Murillas J, Miquel R, et al. Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of HIV infection? HIV Med 2005;6:135-139.
41. de Mendoza C, Soriano V. The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals. Antivir Ther 2005;10(Suppl 2):M109-M115.
42. Walker UA, Langmann P, Miehle N, Zilly M, Klinker H, Petschner F. Beneficial effects of oral uridine in mitochondrial toxicity. AIDS 2004;18:1085-1086.
43. Banasch M, Goetze O, Knyhala K, Potthoff A, Schlottmann R, Kwiatek MA, et al. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients. AIDS 2006;20:1554-1556.